医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

臨床試験

Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions

Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: an Orally-Administered Gastrointestinal Apros Therapeutics Announces CRC IND Clearance Liver-Targeted TLR7

2020年09月09日

福岛SiC应用技研株式会社在C轮融资中筹得3,000万美元（31亿日元）

福岛SiC应用技研株式会社在C轮融资中筹得3,000万美元（31亿日元）

ヘルスケア医療機器放射線学腫瘍学臨床試験　 TimeLine: 000万美元 31亿日元福岛SiC应用技研株式会社在C轮融资中筹得3

2020年09月08日

Zion Pharma Announces Initiation of Phase 1 Study

Zion Pharma Announces Initiation of Phase 1 Study

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Study Zion Pharma Announces Initiation of Phase

2020年09月08日

赞荣医药宣布启动临床一期研究

赞荣医药宣布启动临床一期研究

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: 赞荣医药宣布启动临床一期研究

2020年09月08日

Fukushima SiC Applied Engineering Inc. Raises USD 30 Million (JPY 3.1 Billion) in Series C Funding

Fukushima SiC Applied Engineering Inc. Raises USD 30 Million (JPY 3.1 Billion) in Series C Funding

ヘルスケア医療機器放射線学腫瘍学臨床試験　 TimeLine: Fukushima SiC Applied Engineering Inc Million Raises USD

2020年09月08日

COVID-19 Testing Labs Can Skip RNA Extraction, Simplifying and Accelerating Workflow, With New Promega XpressAmp™ Direct Amplification Reagents

COVID-19 Testing Labs Can Skip RNA Extraction, Simplifying and Accelerating Workflow, With New Promega XpressAmp™ Direct Amplification Reagents

バイオテクノロジーヘルスケア医療機器感染症病院臨床試験製薬　 TimeLine: COVID-19 Testing Labs Can Skip Direct Amplification Reagents RNA Extraction Simplifying and Accelerating Workflow With New Promega XpressAmp

2020年09月02日

Astex Pharmaceuticals Announces That Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA

Astex Pharmaceuticals Announces That Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins Astex Pharmaceuticals Announces That Tolinapant ASTX660 Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA

2020年09月01日

拓臻生物任命Senthil Sundaram为首席执行官、Mark Vignola, Ph.D.为首席财务官、Erin Quirk, M.D.为总裁

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Erin Quirk M.D.为总裁 Ph.D.为首席财务官 Sundaram为首席执行官拓臻生物任命Senthil

2020年08月28日

BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals

BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals

バイオテクノロジーヘルスケア感染症臨床試験製薬　 TimeLine: Antibodies Developed by Singlomics Biopharmaceuticals BeiGene Announces Exclusive License Agreement for Neutralizing COVID

2020年08月27日

コールバーグとムバダラがPCIファーマ・サービシズの過半数持ち分を取得する正式契約を締結

コールバーグとムバダラがPCIファーマ・サービシズの過半数持ち分を取得する正式契約を締結

バイオテクノロジーヘルスケア医療用品臨床試験製薬　 TimeLine: PCIファーマ・サービシズコールバーグムバダラ締結過半数持ち分

2020年08月27日